Treatment Burden:

Research and development pharmaceutical companies invest massively to find innovative treatments for highly specilaised diseases The reality is that when a new molecule or drug goes to market, it does so with a high price tag.

Medical schemes are often unwilling to re-imburse these drugs or treatment programmes, in part or in full, based on financial obligations to their members.

The AICF shares the pharmaceutical companies' burden of patient access to innovative medicines, and the medical schemes' burden of the financial obligation, by providing financial assistance for defined periods, thereby facilitating patient access to innovative care.